Novo Nordisk Sales Soar, Fortifying Grip on Obesity Drug Market - Bloomberg
Consumer Product Safety Alert: Semaglutides - Ozempic, Wegovy and Rybelsus
Novo Nordisk Earnings Continue to Surge on Blockbuster Weight-Loss Drug Demand -- Update -November 02, 2023 at 03:37 am EDT
Prescriptions for popular diabetes and weight-loss drugs soared, but access is limited for some patients
The Ozempic-killers already delivering fat profits
Is Semaglutide - Novo Nordisk's Keytruda?
Novo's Wegovy supply rebound on track for later this year as demand stays strong
1 Green Flag and 1 Red Flag for Novo Nordisk
CEOs' Israel war footing
Novo Nordisk: Is This Your Rainy Day Fund? I Think So! (NYSE:NVO)
Ozempic-maker Novo Nordisk briefly becomes Europe's most valuable firm